BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34550666)

  • 1. Myfembree for fibroid-associated heavy menstrual bleeding.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):121-123. PubMed ID: 34550666
    [No Abstract]   [Full Text] [Related]  

  • 2. Oriahnn for fibroid-associated heavy menstrual bleeding.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):51-52. PubMed ID: 33830967
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
    N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
    Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
    Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
    Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
    N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
    Syed YY
    Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
    Muhammad J; Yusof Y; Ahmad I; Norhayati MN
    BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
    Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
    Ali M; Chen HY; Chiang YF; Badary OA; Hsia SM; Al-Hendy A
    Expert Opin Pharmacother; 2022 Mar; 23(4):421-429. PubMed ID: 35068291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
    Lynch SE; Mayer DC
    Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
    Ali M; A R S; Al Hendy A
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elagolix, Estradiol, and Norethindrone Kit (Oriahnn) for the Management of Heavy Menstrual Bleeding Associated with Fibroids.
    Antoun J
    Am Fam Physician; 2021 Apr; 103(8):505-506. PubMed ID: 33856165
    [No Abstract]   [Full Text] [Related]  

  • 14. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
    Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
    Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
    Blair HA
    Drugs; 2024 Apr; 84(4):449-457. PubMed ID: 38592603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relugolix: First Global Approval.
    Markham A
    Drugs; 2019 Apr; 79(6):675-679. PubMed ID: 30937733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
    Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
    Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
    Osuga Y; Enya K; Kudou K; Hoshiai H
    Fertil Steril; 2019 Nov; 112(5):922-929.e2. PubMed ID: 31594635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relugolix for the treatment of uterine fibroids.
    Rocca ML; Palumbo AR; Lico D; Fiorenza A; Bitonti G; D'Agostino S; Gallo C; Di Carlo C; Zullo F; Venturella R
    Expert Opin Pharmacother; 2020 Oct; 21(14):1667-1674. PubMed ID: 32674616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
    Neblett MF; Stewart EA
    Obstet Gynecol; 2023 May; 141(5):901-910. PubMed ID: 37103532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.